HexaHealth
Series A in 2025
HexaHealth is a startup focused on transforming the healthcare landscape by creating a comprehensive network of hospitals nationwide. The company leverages digital solutions to enhance patient care throughout the entire surgical process, addressing the prevalent issue of information asymmetry in the medical field. By utilizing an advanced artificial intelligence-powered recommendation engine, HexaHealth's platform facilitates the identification of suitable doctors and hospitals for patients, ensuring a streamlined experience for hospital admissions, insurance coordination, financing, and post-surgery recovery. This approach not only promotes transparency and accessibility within the medical industry but also empowers patients with the necessary knowledge to make informed decisions regarding their healthcare.
HexaHealth
Seed Round in 2022
HexaHealth is a startup focused on transforming the healthcare landscape by creating a comprehensive network of hospitals nationwide. The company leverages digital solutions to enhance patient care throughout the entire surgical process, addressing the prevalent issue of information asymmetry in the medical field. By utilizing an advanced artificial intelligence-powered recommendation engine, HexaHealth's platform facilitates the identification of suitable doctors and hospitals for patients, ensuring a streamlined experience for hospital admissions, insurance coordination, financing, and post-surgery recovery. This approach not only promotes transparency and accessibility within the medical industry but also empowers patients with the necessary knowledge to make informed decisions regarding their healthcare.
HexaHealth
Seed Round in 2021
HexaHealth is a startup focused on transforming the healthcare landscape by creating a comprehensive network of hospitals nationwide. The company leverages digital solutions to enhance patient care throughout the entire surgical process, addressing the prevalent issue of information asymmetry in the medical field. By utilizing an advanced artificial intelligence-powered recommendation engine, HexaHealth's platform facilitates the identification of suitable doctors and hospitals for patients, ensuring a streamlined experience for hospital admissions, insurance coordination, financing, and post-surgery recovery. This approach not only promotes transparency and accessibility within the medical industry but also empowers patients with the necessary knowledge to make informed decisions regarding their healthcare.
Axio Biosolutions
Series B in 2020
Axio Biosolutions Private Limited is a medical technology company based in Ahmedabad, India, specializing in the development and commercialization of advanced surgical and wound care products. Established in 2007, the company focuses on creating innovative solutions for wound dressings, particularly in pre-hospital emergency care and surgical applications. Its flagship product, AXIOSTAT, is a sterile, non-absorbable haemostatic dressing designed to control bleeding in various traumatic injuries, such as combat and road accidents, as well as surgical procedures. AXIOSTAT is notable for being the first Indian product to receive USFDA clearance for wound care and hemostatic applications. The company primarily serves hospitals, trauma care services, emergency responders, law enforcement, military, and sports officials, addressing the critical need to manage life-threatening bleeding.
Onco is a healthcare technology company that offers an online platform specifically designed for cancer patients and their families. This platform facilitates personalized treatment advice and comprehensive care management by connecting users with oncologists and other healthcare providers through a mobile application. Onco enables patients to receive unbiased analyses of their treatment plans, along with detailed and personalized reports regarding their condition. By prioritizing connections with hospitals, diagnostic labs, and service providers, Onco ensures that patients have access to essential medical advice and support whenever they need it, thereby enhancing their overall treatment journey.
Axio Biosolutions
Series B in 2018
Axio Biosolutions Private Limited is a medical technology company based in Ahmedabad, India, specializing in the development and commercialization of advanced surgical and wound care products. Established in 2007, the company focuses on creating innovative solutions for wound dressings, particularly in pre-hospital emergency care and surgical applications. Its flagship product, AXIOSTAT, is a sterile, non-absorbable haemostatic dressing designed to control bleeding in various traumatic injuries, such as combat and road accidents, as well as surgical procedures. AXIOSTAT is notable for being the first Indian product to receive USFDA clearance for wound care and hemostatic applications. The company primarily serves hospitals, trauma care services, emergency responders, law enforcement, military, and sports officials, addressing the critical need to manage life-threatening bleeding.
TMiRob is a developer of medical robots focused on enhancing operational efficiency in hospital and clinical settings. The company creates advanced robotic solutions that assist medical staff in various tasks, including the management of high-value consumables, delivery of infusion packages, and distribution of instruments. Additionally, TMiRob's technology supports intelligent management systems for medicine cabinets and facilitates the disposal of medical waste. By streamlining these processes, TMiRob aims to reduce labor costs and improve overall management efficiency in healthcare environments.
Axio Biosolutions
Series A in 2016
Axio Biosolutions Private Limited is a medical technology company based in Ahmedabad, India, specializing in the development and commercialization of advanced surgical and wound care products. Established in 2007, the company focuses on creating innovative solutions for wound dressings, particularly in pre-hospital emergency care and surgical applications. Its flagship product, AXIOSTAT, is a sterile, non-absorbable haemostatic dressing designed to control bleeding in various traumatic injuries, such as combat and road accidents, as well as surgical procedures. AXIOSTAT is notable for being the first Indian product to receive USFDA clearance for wound care and hemostatic applications. The company primarily serves hospitals, trauma care services, emergency responders, law enforcement, military, and sports officials, addressing the critical need to manage life-threatening bleeding.
Perfint Healthcare
Series D in 2012
Perfint Healthcare is a leading developer of medical devices that specialize in planning and targeting solutions for image-guided interventional procedures, focusing primarily on oncology and pain management. The company's innovative products are designed to facilitate minimally invasive treatments, such as biopsies, drug delivery, ablation, drainage, and fine needle aspiration. These devices are utilized by radiologists in some of the world’s top hospitals, enhancing the capabilities of healthcare professionals to improve patient outcomes in both cancer-related and non-cancer-related pain management. Perfint's solutions are recognized for their quality and effectiveness, as evidenced by their CE marking, which signifies compliance with European health and safety standards.
Perfint Healthcare
Series C in 2012
Perfint Healthcare is a leading developer of medical devices that specialize in planning and targeting solutions for image-guided interventional procedures, focusing primarily on oncology and pain management. The company's innovative products are designed to facilitate minimally invasive treatments, such as biopsies, drug delivery, ablation, drainage, and fine needle aspiration. These devices are utilized by radiologists in some of the world’s top hospitals, enhancing the capabilities of healthcare professionals to improve patient outcomes in both cancer-related and non-cancer-related pain management. Perfint's solutions are recognized for their quality and effectiveness, as evidenced by their CE marking, which signifies compliance with European health and safety standards.
Perfint Healthcare
Series B in 2010
Perfint Healthcare is a leading developer of medical devices that specialize in planning and targeting solutions for image-guided interventional procedures, focusing primarily on oncology and pain management. The company's innovative products are designed to facilitate minimally invasive treatments, such as biopsies, drug delivery, ablation, drainage, and fine needle aspiration. These devices are utilized by radiologists in some of the world’s top hospitals, enhancing the capabilities of healthcare professionals to improve patient outcomes in both cancer-related and non-cancer-related pain management. Perfint's solutions are recognized for their quality and effectiveness, as evidenced by their CE marking, which signifies compliance with European health and safety standards.
Perfint Healthcare
Series A in 2007
Perfint Healthcare is a leading developer of medical devices that specialize in planning and targeting solutions for image-guided interventional procedures, focusing primarily on oncology and pain management. The company's innovative products are designed to facilitate minimally invasive treatments, such as biopsies, drug delivery, ablation, drainage, and fine needle aspiration. These devices are utilized by radiologists in some of the world’s top hospitals, enhancing the capabilities of healthcare professionals to improve patient outcomes in both cancer-related and non-cancer-related pain management. Perfint's solutions are recognized for their quality and effectiveness, as evidenced by their CE marking, which signifies compliance with European health and safety standards.